EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2019-2028

  • You are here:
  • Home
  • Reports
  • EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2019-2028

EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2019-2028

The Europe kidney cancer therapeutics and diagnostics market is projected to register a CAGR of 5.36% during the forecast period, 2019-2028. The rising incidence of kidney cancer cases and the increasing prevalence of transplants are among the primary drivers of market growth in the region. The United Kingdom, Germany, France, Russia, Italy, Poland, Belgium, and the rest of Europe, are assessed for the Europe kidney cancer therapeutics and diagnostics market growth analysis. Germany has the presence of major market players.

EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2019-2028

Europe Kidney Cancer Therapeutics and Diagnostics Market by Cancer Type (Clear Cell Rcc, Papillary Rcc, Chromophobe Rcc, Urothelial Carcinoma/transitional Cell Carcinoma, Other Kidney Cancers) by Component (Drugs (Drugs by Therapeutic Class (Targeted Therapy, Immunotherapy, Other Therapeutic Class), Drugs by Pharmacologic Class(Angiogenesis Inhibitors, Mtor Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (Il-2))), Diagnostics) and by Geography.

Request free sample

The Europe kidney cancer therapeutics and diagnostics market is projected to register a CAGR of 5.36% during the forecast period, 2019-2028. The rising incidence of kidney cancer cases and the increasing prevalence of transplants are among the primary drivers of market growth in the region.
europe-kidney-cancer-therapeutics-and- diagnostics-market

To know more about this report, request a free sample copy

The United Kingdom, Germany, France, Russia, Italy, Poland, Belgium, and the rest of Europe, are assessed for the Europe kidney cancer therapeutics and diagnostics market growth analysis. Germany has the presence of major market players. Every year the country has hundreds of medical tourists seeking kidney cancer treatment, given the quality and affordability. As per the Robert Koch Institute, almost 16,500 are diagnosed with kidney cancer in the country every year. Many large university hospitals have been successful in the diagnosis and treatment of the disease. One such institution is the University Hospital Charite in Berlin.

In the UK, the surging cases have resulted in increased demands for the development of novel therapeutics and diagnostics. As per the estimations of Globocan, in 2018, there were 13,683 new cases, which is expected to increase during the forecast period. The last decade has witnessed an increase of nearly 47%, and is set to further rise by 26% in the coming years. Several initiatives by the public and private entities are set to drive the growth of the market. The UK affiliate of Ipsen introduced the innovative Cabometyx (cabozantinib) via NHS Scotland in 2017 for patients with advanced kidney cancer. This was after the announcement by the Scottish Medicines Consortium (SMC).

F. Hoffmann-La Roche Ltd develops and commercializes innovative diagnostic and therapeutic products. It manufactures pharmaceutical products in areas like neuroscience, oncology, infectious diseases, immunology, etc. The company provides its services to hospitals, commercial diagnostics laboratories, healthcare professionals, researchers, pharmacists, etc. The company operates in Europe, Latin America, North America, etc. with its headquarters in Basel, Switzerland.

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    • MARKET DEFINITION
    •    KEY DRIVERS
      • GROWING PREVALENCE OF KIDNEY CANCER CASES
      • INCREASING USAGES OF MINIMALLY INVASIVE PROCESSES
      • SURGING RESEARCH AND DEVELOPMENT EXPENDITURE
    •    KEY RESTRAINTS
      • HIGH COSTS ASSOCIATED WITH THE TREATMENT AND DIAGNOSIS OF KIDNEY CANCER
      • LOW RATE OF SUCCESS IN THE CLINICAL TRIALS OF KIDNEY CANCER DRUGS
      • STRINGENT REGULATIONS
  1. KEY ANALYTICS
    •    PORTER’S FIVE FORCE ANALYSIS
      • THREAT OF NEW ENTRY
      • THREAT OF SUBSTITUTION
      • BUYER’S POWER
      • SUPPLIER’S POWER
      • COMPETITIVE RIVALRY
    • IMPACT OF COVID-19 ON KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
    • KEY INVESTMENT INSIGHT
  2. MARKET BY CANCER TYPE
    • CLEAR CELL RCC
    • PAPILLARY RCC
    • CHROMOPHOBE RCC
    • UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA
    • OTHER KIDNEY CANCERS
  3. MARKET BY COMPONENT
    •    DRUGS
      •    DRUGS BY THERAPEUTIC CLASS
        • TARGETED THERAPY
        • IMMUNOTHERAPY
        • OTHER THERAPEUTIC CLASS
      •    DRUGS BY PHARMACOLOGIC CLASS
        • ANGIOGENESIS INHIBITORS
        • MTOR INHIBITORS
        • MONOCLONAL ANTIBODIES
        • CYTOKINE IMMUNOTHERAPY (IL-2)
    •    DIAGNOSTICS
      • IMAGING TEST
      • BIOPSY
      • BLOOD TEST
      • OTHER DIAGNOSTICS
  1. GEOGRAPHICAL ANALYSIS
    •    EUROPE
      • GERMANY
      • THE UNITED KINGDOM
      • FRANCE
      • ITALY
      • RUSSIA
      • BELGIUM
      • POLAND
      • REST OF EUROPE
  1. COMPANY PROFILES
    • ABBOTT LABORATORIES
    • AMGEN INC
    • BAYER AG
    • BECTON, DICKINSON AND COMPANY (BD)
    • BRISTOL-MYERS SQUIBB COMPANY
    • EXELIXIS
    • HOFFMANN-LA ROCHE
    • MERCK & CO INC
    • MERCK KGAA
    • NOVARTIS INTERNATIONAL AG
    • NXSTAGE MEDICAL INC
    • PFIZER INC
    • SEATTLE GENETIC

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS

TABLE 2: RISK FACTORS DEVELOPING KIDNEY CANCER

TABLE 3: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 4: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 5: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 6: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 7: EUROPE THERAPEUTIC CLASS DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 8: EUROPE THERAPEUTIC CLASS DRUGS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 9: EUROPE PHARMACOLOGIC CLASS DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 10: EUROPE PHARMACOLOGIC CLASS DRUGS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 11: EUROPE DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 12: EUROPE DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 13: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 14: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

LIST OF FIGURES

FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, IN 2019

FIGURE 5: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CLEAR CELL RCC, 2019-2028 (IN $ MILLION)

FIGURE 6: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY PAPILLARY RCC, 2019-2028 (IN $ MILLION)

FIGURE 7: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CHROMOPHOBE RCC, 2019-2028 (IN $ MILLION)

FIGURE 8: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA, 2019-2028 (IN $ MILLION)

FIGURE 9: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY OTHER KIDNEY CANCERS, 2019-2028 (IN $ MILLION)

FIGURE 10: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, IN 2019

FIGURE 11: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUGS, 2019-2028 (IN $ MILLION)

FIGURE 12: EUROPE THERAPEUTIC DRUG CLASS MARKET, BY TARGETED THERAPY, 2019-2028 (IN $ MILLION)

FIGURE 13: EUROPE THERAPEUTIC DRUG CLASS MARKET, BY IMMUNOTHERAPY, 2019-2028 (IN $ MILLION)

FIGURE 14: EUROPE THERAPEUTIC DRUG CLASS MARKET, BY OTHER THERAPEUTIC CLASS, 2019-2028 (IN $ MILLION)

FIGURE 15: EUROPE PHARMACOLOGIC CLASS MARKET, BY ANGIOGENESIS INHIBITORS, 2019-2028 (IN $ MILLION)

FIGURE 16: EUROPE PHARMACOLOGIC CLASS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)

FIGURE 17: EUROPE PHARMACOLOGIC CLASS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)

FIGURE 18: EUROPE PHARMACOLOGIC CLASS MARKET, BY CYTOKINE IMMUNOTHERAPY (IL-2), 2019-2028 (IN $ MILLION)

FIGURE 19: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2019-2028 (IN $ MILLION)

FIGURE 20: EUROPE DIAGNOSTICS MARKET, BY IMAGING TEST, 2019-2028 (IN $ MILLION)

FIGURE 21: EUROPE DIAGNOSTICS MARKET, BY BIOPSY, 2019-2028 (IN $ MILLION)

FIGURE 22: EUROPE DIAGNOSTICS MARKET, BY BLOOD TEST, 2019-2028 (IN $ MILLION)

FIGURE 23: EUROPE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2019-2028 (IN $ MILLION)

FIGURE 24: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 25: GERMANY KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 26: THE UNITED KINGDOM KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 27: FRANCE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 28: ITALY KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 29: RUSSIA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 30: BELGIUM KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 31: POLAND KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

FIGURE 32: REST OF EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)

  1. GEOGRAPHICAL ANALYSIS
    •    EUROPE
      • GERMANY
      • THE UNITED KINGDOM
      • FRANCE
      • ITALY
      • RUSSIA
      • BELGIUM
      • POLAND
      • REST OF EUROPE
  1. MARKET BY CANCER TYPE
    • CLEAR CELL RCC
    • PAPILLARY RCC
    • CHROMOPHOBE RCC
    • UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA
    • OTHER KIDNEY CANCERS
  2. MARKET BY COMPONENT
    •    DRUGS
      •    DRUGS BY THERAPEUTIC CLASS
        • TARGETED THERAPY
        • IMMUNOTHERAPY
        • OTHER THERAPEUTIC CLASS
      •    DRUGS BY PHARMACOLOGIC CLASS
        • ANGIOGENESIS INHIBITORS
        • MTOR INHIBITORS
        • MONOCLONAL ANTIBODIES
        • CYTOKINE IMMUNOTHERAPY (IL-2)
    •    DIAGNOSTICS
      • IMAGING TEST
      • BIOPSY
      • BLOOD TEST
      • OTHER DIAGNOSTICS

To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now